S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:BLRX

BioLineRx (BLRX) Stock Price, News & Analysis

$1.12
+0.01 (+0.90%)
(As of 03/28/2024 ET)
Today's Range
$1.10
$1.13
50-Day Range
$1.03
$1.39
52-Week Range
$0.81
$2.53
Volume
163,168 shs
Average Volume
321,412 shs
Market Capitalization
$81.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

BioLineRx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,775.0% Upside
$21.00 Price Target
Short Interest
Healthy
0.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of BioLineRx in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.91) to ($0.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.99 out of 5 stars

Medical Sector

628th out of 938 stocks

Pharmaceutical Preparations Industry

284th out of 420 stocks

BLRX stock logo

About BioLineRx Stock (NASDAQ:BLRX)

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.

BLRX Stock Price History

BLRX Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
BioLineRx (NASDAQ:BLRX) Upgraded by StockNews.com to "Sell"
BLRX: First Aphexda Sales Recognized
BioLineRx's (BLRX) "Buy" Rating Reaffirmed at HC Wainwright
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
BioLineRx (BLRX) Scheduled to Post Earnings on Tuesday
BLRX Mar 2024 1.000 call
BLRX: Poster Presentations
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
BLRX May 2024 1.000 put
BioLineRx: Still A Buy, With Some Questions
BLRX: A Series of Fortunate Events
See More Headlines
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BLRX
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+1,775.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.80 million
Book Value
$0.83 per share

Miscellaneous

Free Float
71,642,000
Market Cap
$81.13 million
Optionable
Optionable
Beta
1.40
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Philip A. Serlin CPA (Age 64)
    M.B.A., CPA, MBA, Chief Executive Officer
    Comp: $635k
  • Ms. Mali Zeevi CPA (Age 48)
    CPA, Chief Financial Officer
    Comp: $380k
  • Dr. Ella Sorani (Age 56)
    Chief Development Officer
    Comp: $457k
  • Ms. Holly W. May M.B.A. (Age 62)
    President of BioLineRx USA
    Comp: $328k
  • Mr. John Lacey
    Head of Corporate Communications & Investor Relations
  • Mr. Adam Janoff Esq.
    General Counsel & Head of Compliance
  • Ms. Tsipi Keren-Lehrer B.Sc.
    L.L.B., Head of BD & Strategic Advisor
  • Mr. Raziel Fried
    Treasurer & Budgetary Control Director

BLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioLineRx stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLRX shares.
View BLRX analyst ratings
or view top-rated stocks.

What is BioLineRx's stock price target for 2024?

1 brokerages have issued twelve-month target prices for BioLineRx's shares. Their BLRX share price targets range from $21.00 to $21.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 1,775.0% from the stock's current price.
View analysts price targets for BLRX
or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2024?

BioLineRx's stock was trading at $1.57 at the start of the year. Since then, BLRX shares have decreased by 28.7% and is now trading at $1.12.
View the best growth stocks for 2024 here
.

Are investors shorting BioLineRx?

BioLineRx saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 324,700 shares, an increase of 76.6% from the February 29th total of 183,900 shares. Based on an average daily trading volume, of 316,300 shares, the short-interest ratio is currently 1.0 days.
View BioLineRx's Short Interest
.

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our BLRX earnings forecast
.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) posted its quarterly earnings data on Tuesday, March, 26th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. The biotechnology company earned $4.80 million during the quarter, compared to analysts' expectations of $0.17 million. During the same period in the previous year, the company posted ($0.09) EPS.

What other stocks do shareholders of BioLineRx own?
Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by many different retail and institutional investors. Top institutional investors include PVG Asset Management Corp (0.09%), Envestnet Asset Management Inc. (0.06%), NorthRock Partners LLC (0.02%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners